Thoma Bravo is acquiring WWEX Group from a consortium of investors including CVC Capital Partners Fund VIII, Providence Equity Partners, Ridgemont Equity Partners and PSG. As part of this transaction, ...

Thoma Bravo to acquire WWEX Group from a CVC-led consortium, combine it with portfolio company Auctane, creating a logistics ...

Dallas-based logistics services provider WWEX Group — which reports billions in annual revenue — has agreed to be acquired by ...

The private-equity firm plans to combine it with Auctane, its shipping and fulfillment portfolio company.

Thoma Bravo has agreed to acquire WWEX Group, a Dallas-based third-party logistics provider of parcel and freight services.

Thoma Bravo is in advanced talks to acquire third-party logistics provider WWEX Group Inc., according to people familiar with the matter, as part of a plan to create a shipping technology business ...

U.S. private ​equity firm Thoma Bravo ‌is in advanced talks to buy third-party logistics provider ​WWEX Group to create ​a shipping technology business worth ⁠as much as $12 billion, ​Bloomberg News ...

Worldwide sovereign cloud infrastructure-as-a-service (IaaS) spending is expected to increase by 36% to $80 billion in 2026, according to Gartner. The rise shows growing global interest in keeping ...

The Trump administration announced that the company, a pharmacy benefit manager, had agreed to make significant changes to its practices. By Rebecca Robbins and Reed Abelson The reporters have ...

KANSAS CITY, Mo. (KCTV) - The 69 Highway express lane in Overland Park will open February 21, at 8 a.m., becoming the Kansas City metro’s only express toll and the second in Kansas. The new toll lane ...

The American Express returns to the Pete Dye Stadium Course in La Quinta, California, and features a $9.2 million purse. The 7,210-yard, par-72 course will host the field competing for the title and ...

Worldwide Clinical Trials is expanding its horizons with the acquisition of Catalyst Clinical Research, a specialist oncology organization with a particular knack for early-stage cancer trials. The ...